Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
暂无分享,去创建一个
A. Hauschild | J. Kirkwood | P. Hersey | C. Robert | P. Lorigan | J. Gómez-Navarro | D. McDermott | C. Bulanhagui | Jane Q. Liang | M. Marshall
[1] J. Stockman. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2010 .
[2] A. Hauschild,et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] B. Redman,et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Weber. Ipilimumab: controversies in its development, utility and autoimmune adverse events , 2009, Cancer Immunology, Immunotherapy.
[5] V. Sondak,et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Grou , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Kirkwood,et al. Next generation of immunotherapy for melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Hauschild,et al. EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. , 2008 .
[8] S. Chanock,et al. Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade , 2008, Journal of immunotherapy.
[9] H. Pehamberger,et al. Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies , 2008 .
[10] B. Redman,et al. Prognostic role of prior cytokine immunotherapy in outcome of treatment with tremelimumab (CP-675,206) in patients with metastatic melanoma , 2008 .
[11] L. Wood,et al. Pharmacogenetic analysis of CTLA4 gene polymorphisms and response to tremelimumab in patients with advanced melanoma , 2008 .
[12] Pl Chen,et al. Family-based association study of cytotoxic T-lymphocyte antigen-4 with susceptibility to Graves' disease in Han population of Taiwan , 2008, Genes and Immunity.
[13] Donna Niedzwiecki,et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P. Hwu,et al. Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma , 2008, Cancer investigation.
[15] S. O’Day,et al. Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) , 2007, Cancer.
[16] P. Lorigan,et al. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Kirkwood,et al. Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials , 2007 .
[18] V. Sondak,et al. Chemotherapy for metastatic melanoma , 2007, Cancer.
[19] H. Pehamberger,et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] B. Comin-Anduix,et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Vicente,et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus , 2004, European Journal of Human Genetics.
[22] J. Manola,et al. A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma , 2004, Clinical Cancer Research.
[23] M. Gore,et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. , 2003, Cancer treatment reviews.
[24] Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) , 2003 .
[25] B. Foster,et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. , 2000, Cancer research.
[26] H. Fukuda,et al. European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .
[27] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[28] D. Schadendorf,et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] B. Foster,et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[30] J. Allison,et al. Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.
[31] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] M. Atkins,et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Kirkwood,et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. Allison,et al. Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.
[35] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .